Posted by Michael Wonder on 24 Feb 2025
Auron Therapeutics announces AUTX-703 granted fast track designation by the FDA for relapsed or refractory acute myelogenous leukaemia
24 February 2025 - Auron Therapeutics today announced that the US FDA has granted fast track designation to AUTX-703 for the treatment of patients with relapsed or refractory acute myelogenous leukaemia.
AUTX-703 is a novel, first in class, oral KAT2A/B degrader discovered and developed by Auron using its AURIGIN platform.
